DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Real-time Boerse Frankfurt Warrants 13:20:30 20/06/2024 BST | ||
| 35.86 EUR | -0.08% |
|
| Current month | +1.41% | ||
| 1 month | -4.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 35.86 | -0.08% |
| 19/06/24 | 35.89 | +0.36% |
| 18/06/24 | 35.76 | -0.61% |
| 17/06/24 | 35.98 | -1.18% |
| 14/06/24 | 36.41 | +0.08% |
Real-time Boerse Frankfurt Warrants
Last update June 20, 2024 at 01:20 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC4GWB |
| ISIN | DE000PC4GWB9 |
| Date issued | 02/02/2024 |
| Maturity | 21/03/2025 (274 Days) |
| Parity | 1 : 1 |
| Emission price | 38.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 41.79 € |
|---|---|
| Lowest since issue | 34.89 € |
| Spread | 0.22 € |
| Spread % | 0.61% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.81
USD
Average target price
53.19
USD
Spread / Average Target
+30.35%
- Stock Market
- Certificates
- Certificat
